Hecht Peter M 4/A

Accession 0001209191-19-050311

CIK 0001755237other

Filed

Sep 19, 8:00 PM ET

Accepted

Sep 20, 4:05 PM ET

Size

24.2 KB

Accession

0001209191-19-050311

Form 4/AAmended

Period: 2019-04-01

Director10% Owner

Transactions

Award
Common Stock
2019-04-01+221,736→ 221,736 total
Award
Employee Stock Option (Right to Buy)
2019-04-01+53,083→ 53,083 total
Exercise: $12.24Exp: 2021-02-01→ Common Stock (53,083 underlying)
Award
Employee Stock Option (Right to Buy)
2019-04-01+36,088→ 36,088 total
Exercise: $16.21Exp: 2022-02-01→ Common Stock (36,088 underlying)
Award
Employee Stock Option (Right to Buy)
2019-04-01+37,972→ 37,972 total
Exercise: $15.54Exp: 2024-03-03→ Common Stock (37,972 underlying)
Award
Employee Stock Option (Right to Buy)
2019-04-01+223,893→ 223,893 total
Exercise: $11.28Exp: 2026-03-01→ Common Stock (223,893 underlying)
Award
Employee Stock Option (Right to Buy)
2019-04-01+380,330→ 380,330 total
Exercise: $16.02Exp: 2028-02-21→ Common Stock (380,330 underlying)
Award
Employee Stock Option (Right to Buy)
2019-04-01+43,679→ 43,679 total
Exercise: $14.40Exp: 2023-02-01→ Common Stock (43,679 underlying)
Award
Employee Stock Option (Right to Buy)
2019-04-01+344,777→ 344,777 total
Exercise: $18.47Exp: 2027-02-27→ Common Stock (344,777 underlying)
Award
Employee Stock Option (Right to Buy)
2019-04-01+857,830→ 857,830 total
Exercise: $14.21Exp: 2029-01-29→ Common Stock (857,830 underlying)

Footnotes (8)

[F1]This report has been amended to reflect the number of shares received in a pro rata distribution by Ironwood Pharmaceuticals, Inc. ("Ironwood") as a result of the spin-off of the Issuer from Ironwood, effective on April 1, 2019 (the "Separation").
[F2]This report has been amended to correct the exercise price of the stock options that were originally issued by Ironwood in connection with the Separation.
[F3]This option, granted as an annual performance award, is presently exercisable in full.
[F4]This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation.
[F5]The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2016.
[F6]The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2017.
[F7]The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2018.
[F8]The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2019.

Documents

1 file

Cyclerion Therapeutics, Inc.

CIK 0001755237

Entity typeother